Evidence map›Paper›PMID 26998057›Full record

ArticleOncology letters2016

Assessment of

Qing Huang, Qiuhua Deng, Lei Jiang, Rong Fang, Yinghua Qiu, Ping Wang, Jeff X Zhou, Haihong Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qing HuangDepartment of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China.
Qiuhua DengDepartment of Thoracic Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China.
Lei JiangDepartment of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China.
Rong FangDepartment of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China.
Yinghua QiuUnigene Bioscience Co., Ltd., Ningbo, Zhejiang 315211, P.R. China.
Ping WangDepartment of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China.
Jeff X ZhouDepartment of Pathology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China.
Haihong YangDepartment of Thoracic Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China.
Ningbo University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNBioscience (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase (ALK) gene fusion is a driving mutation underlying the development of non-small cell lung cancer (NSCLC). Accurate detection of ALK fusion is critical for the use of ALK inhibitors in the treatment of NSCLC. Commonly utilized methods for ALK detection include fluorescence

Indexed as

anaplastic lymphoma kinasecrizotiniblung cancertargeted therapy

Identifiers

PMID26998057
PMCPMC4774594
OpenAlexW2266112379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.